Literature DB >> 24700884

Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.

Seung Hwan Moon1, Ho Seong Kim, Seung Hyup Hyun, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Kyung-Han Lee, Byung-Tae Kim, Joon Young Choi.   

Abstract

UNLABELLED: The aim of this study was to investigate the value of (18)F-FDG parameters of the primary tumor in predicting occult lymph node metastasis in patients with clinically N0 esophageal squamous cell carcinoma.
METHODS: The study comprised 143 consecutive patients (mean age ± SD, 63.9 ± 8.6 y; range, 31.8-81.2 y) from May 2003 to January 2010 who had clinically N0 esophageal squamous cell carcinoma based on preoperative imaging studies including chest CT, (18)F-FDG PET/CT, and endoscopic ultrasound. We measured maximum standardized uptake value (SUV max), mean SUV (SUV mean), total lesion glycolysis (TLG), and metabolic tumor volume (MTV) of the primary tumor and analyzed the relationship between clinicopathologic variables including PET parameters and occult lymph node metastasis using a logistic regression model.
RESULTS: Univariate analysis indicated that clinical T classification, SUV max, SUV mean, MTV, TLG, and longitudinal diameter of tumor were significant risk factors associated with occult lymph node metastasis. Optimal thresholds were cT2-4, SUV max ≥ 4.8, SUV mean ≥ 3.2, MTV ≥ 5.5 cm(3), TLG ≥ 220, and diameter ≥ 3.8 cm. After multivariate analysis, the logistic regression model revealed that clinical T classification (hazard ratio [HR], 4.6; 95% confidence interval [CI], 1.7-12.4; P = 0.003) and SUV max (HR, 3.5; 95% CI, 1.3-9.2; P = 0.012) were independent risk factors. The combination of SUV max and clinical T classification (HR, 13.2; 95% CI, 5.4-31.9; P < 0.001) was a significantly better powerful risk factor for occult lymph node metastasis than SUV max or clinical T classification alone. Sensitivity, specificity, positive predictive value, and negative predictive value of the combination of clinical T classification and SUV max were 73.0%, 81.5%, 60.0%, and 89.7%, respectively.
CONCLUSION: SUV max, combined with clinical T classification, may be useful for predicting occult lymph node metastasis in patients with clinically N0 squamous cell carcinoma of the esophagus.

Entities:  

Keywords:  18F-FDG; PET/CT; SUVmax; esophageal cancer; lymph node; occult metastasis

Mesh:

Substances:

Year:  2014        PMID: 24700884     DOI: 10.2967/jnumed.113.130716

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Dual-time point 18F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes.

Authors:  Sohyun Park; Jin Chul Paeng; Chang Hyun Kang; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-03       Impact factor: 9.236

2.  Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.

Authors:  John M Findlay; Richard S Gillies; James M Franklin; Eugene J Teoh; Greg E Jones; Sara di Carlo; Fergus V Gleeson; Nicholas D Maynard; Kevin M Bradley; Mark R Middleton
Journal:  Eur Radiol       Date:  2016-02-16       Impact factor: 5.315

3.  Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis.

Authors:  Jingfeng Hu; Dengyan Zhu; Yang Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

4.  Development and validation of a nomogram model for the prediction of 4L lymph node metastasis in thoracic esophageal squamous cell carcinoma.

Authors:  Lei Xu; Jia Guo; Shu Qi; Hou-Nai Xie; Xiu-Feng Wei; Yong-Kui Yu; Ping Cao; Rui-Xiang Zhang; Xian-Kai Chen; Yin Li
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.